Sorafenib cardiotoxicity increases mortality after myocardial infarction.

ABSTRACT:

Rationale

Sorafenib is an effective treatment for renal cell carcinoma, but recent clinical reports have documented its cardiotoxicity through an unknown mechanism.

Objective

Determining the mechanism of sorafenib-mediated cardiotoxicity.

Methods and results

Mice treated with sorafenib or vehicle for 3 weeks underwent induced myocardial infarction (MI) after 1 week of treatment. Sorafenib markedly decreased 2-week survival relative to vehicle-treated controls, but echocardiography at 1 and 2 weeks post MI detected no differences in cardiac function. Sorafenib-treated hearts had significantly smaller diastolic and systolic volumes and reduced heart weights. High doses of sorafenib induced necrotic death of isolated myocytes in vitro, but lower doses did not induce myoc

SUBMITTER: Duran JM 

PROVIDER: S-EPMC4037647 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature